Placebo News and Research

RSS

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.

18 May 2011

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.

18 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

Anavex comments on new Alzheimer’s disease diagnostic guidelines

Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated for the first time in more than 25 years. The new guidelines discuss the importance of new technologies, including brain imaging and biomarker analysis, in research and clinical diagnosis. They describe Alzheimer’s disease at a preclinical stage, Mild Cognitive Impairment (MCI) due to Alzheimer’s disease, and dementia due to Alzheimer’s pathology.

18 May 2011

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available.

17 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients

Cumberland Pharmaceuticals Inc. today announced that results from a clinical study evaluating the safety and efficacy of Caldolor Injection in treating fever and pain in hospitalized burn patients was published in Volume 32, Number 1 of the Journal of Burn Care & Research.

16 May 2011

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

Pacira Pharmaceuticals, Inc., an emerging specialty pharmaceutical company, today announced that positive results from its Phase 3 study evaluating EXPAREL in patients following hemorrhoidectomy will be presented at the 2011 American Society of Colon and Rectal Surgeons Annual Scientific Meeting in Vancouver, British Columbia.

16 May 2011

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Updated data from a National Cancer Institute-sponsored clinical trial conducted by the Cancer and Leukemia Group (CALGB) was presented May 5 at the 13th International Myeloma Workshop in Paris, France.

16 May 2011

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

The Australian Therapeutic Goods Administration (TGA) has granted approval for FAMPYRA, (fampridine) 10 mg Modified Release (MR) tablet, for the symptomatic improvement of walking ability in adult patients with multiple sclerosis (MS) who have shown improvement after eight weeks of treatment.

16 May 2011

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

\VAYA Pharma announced the availability of Vayarin in pharmacies throughout North Carolina, South Carolina and Texas for children suffering with Attention-Deficit / Hyperactivity Disorder (ADHD).

16 May 2011

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Otsuka Pharmaceutical Co., Ltd. (OPC) and Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) today announced results from a Phase 2 clinical trial of OPC-34712, a novel D2 dopamine partial agonist investigational product.

16 May 2011

Vitamin D may improve exercise capacity, respiratory muscle strength in COPD patients

Vitamin D supplements may help patients with chronic obstructive pulmonary disease (COPD) get more from their pulmonary rehabilitation programs, according to a study conducted by researchers from Belgium.

16 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food & Drug Administration (FDA) to begin clinical study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate.

13 May 2011

Hydroxyurea safe and effective for infants, toddlers with sickle-cell disease

In what is being hailed as a significant advance in the treatment of children with sickle cell anemia, a drug commonly used to treat adults has been shown to be safe and effective in children.

13 May 2011

Aradigm first quarter total revenue decreases to $0.2 million

Aradigm Corporation today announced financial results for the first quarter and three months ended March 31, 2011.

12 May 2011

Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed a phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

12 May 2011

Viewpoints: Tea Party on entitlement reform; Boehner's 'trillions' demand; California's silver tsunami

In a speech on Monday, the speaker of the House said that Republicans would insist on trillions of dollars in spending cuts in exchange for votes to raise the debt limit. He did not mention a time frame. He also did not offer specifics on how he planned to make those cuts. After the beating Republicans took for their plan to slash Medicare, he clearly decided generalities were politically safer. There is no way to solve the country's fiscal ills without an accurate diagnosis and rigorous prescriptions for a cure. Mr. Boehner's speech was devoid of both.

12 May 2011

Placebo News and Research

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Anavex comments on new Alzheimer’s disease diagnostic guidelines

Daiichi Sankyo, Regency Therapeutics launch SPRIX Nasal Spray for severe pain

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

Journal of Burn Care & Research publishes Caldolor clinical study data in hospitalized patients

Positive results from EXPAREL Phase 3 study to be presented at ASCRS Annual Scientific Meeting

New lenalidomide phase III study data presented at 13th International Myeloma Workshop

Australian TGA approves Biogen Idec's FAMPYRA to improve walking ability in patients with MS

VAYA Pharma's Vayarin now available in South, North Carolina and Texas for children with ADHD

Otsuka Pharmaceutical reports OPC-34712 Phase 2 trial results in major depressive disorder

Vitamin D may improve exercise capacity, respiratory muscle strength in COPD patients

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

ZIOPHARM submits IND with FDA for Ad-RTS-IL-12 Phase I study in cancer

Hydroxyurea safe and effective for infants, toddlers with sickle-cell disease

Aradigm first quarter total revenue decreases to $0.2 million

Atox Bio completes AB103 phase 1 study in severe bacterial infections and sepsis

Viewpoints: Tea Party on entitlement reform; Boehner's 'trillions' demand; California's silver tsunami

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News